Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues

HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.

Zacks Investment Research • Feb 18, 2026

Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge

Halozyme Therapeutics is entering a powerful earnings inflection, driven by surging royalty revenue and strategic acquisitions expanding its drug delivery platform. FY25 revenue grew 38% to $1.397 billion, with royalty revenue up 52%; recent acquisitions extend IP life and diversify the technology portfolio. 2026 guidance targets $1.71–$1.81 billion in revenue, over 70% EBITDA growth, and nearly 100% EPS growth, highlighting operating leverage and platform scalability.

Seeking Alpha • Feb 18, 2026

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 18, 2026

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Technology and  Surf Bio's Hyperconcentration Technology Reiterating 2026 Financial Guidance Ranges: Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30% Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1 Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1 SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities. "2025 was a pivotal year for Halozyme as we delivered record total revenue of $1.4 billion, which was the result of continued growth in our ENHANZE business.

PRNewsWire • Feb 17, 2026

Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 18, 2026

Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $2.15. This compares to earnings of $1.26 per share a year ago.

Zacks Investment Research • Feb 17, 2026

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 16, 2026

Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics

Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research • Feb 13, 2026

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results.

PRNewsWire • Feb 10, 2026

Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 10, 2026